Tie-2 Receptor Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tie-2 Receptor Inhibitor The report assesses ...
January 2022
60 pages
TIM-3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “TIM-3 Antagonist The report assesses the active TIM-3 Antagonist ...
January 2022
60 pages
Toll-like-receptor-agonists - Pipeline Insight, 2022
US$ 2,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Toll-Like Receptor Agonist The report assesses the active Toll-Like ...
January 2022
100 pages
Toll-like receptor 4 antagonists - Pipeline Insight, 2022
US$ 1,500.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Toll-Like Receptor 4 (TLR-4) Agonist The report ...
January 2022
60 pages
Toll-like receptor 8 agonists - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Toll-Like Receptor 7, 8 (TLR-8) Agonist The report ...
January 2022
60 pages
Toll-Like Receptor 9 (TLR-9) Modulator - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Toll-Like Receptor 9 (TLR-9) Modulator The report ...
January 2022
60 pages
Toll-Like Receptor Modulators - Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Toll-Like Receptor Modulators The report assesses ...
January 2022
90 pages
Topoisomerase Inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Topoisomerase Inhibitor The report assesses ...
January 2022
90 pages
TRAIL Receptor 1 & Receptor 2 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “TRAIL Receptor 1 & Receptor 2 Agonist The report ...
January 2022
60 pages
Transforming Growth Factor (TGF) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Transforming Growth Factor (TGF) Inhibitor The report ...
January 2022
60 pages
Transforming growth factor beta inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Transforming Growth Factor Beta (TGFb) Inhibitor The ...
January 2022
150 pages
Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist ...
January 2022
60 pages
Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist ...
January 2022
60 pages
Tumor Necrosis Factor Alpha (TNF-a) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tumor Necrosis Factor Alpha (TNF-a) Agonist The report ...
January 2022
60 pages
Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor The ...
January 2022
60 pages
Ubiquitin conjugating enzyme Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ubiquitin conjugating enzyme Inhibitor The report ...
January 2022
60 pages
Ubiquitin Specific Proteases (USP) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ubiquitin Specific Proteases (USP) Inhibitor The report ...
January 2022
60 pages
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vascular Endothelial Growth Factor Inhibitor The report ...
January 2022
90 pages
Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2022
US$ 2,000.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor The ...
January 2022
60 pages
Vasopressin Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vasopressin Receptor Antagonist The report assesses ...
January 2022
60 pages
Vasopressin V1 Receptor (V1R) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vasopressin V1 Receptor (V1R) Antagonist The report ...
January 2022
60 pages
Vasopressin V2 Receptor (V2R) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vasopressin V2 Receptor (V2R) Agonist The report ...
January 2022
60 pages
Vasopressin V2 Receptor (V2R) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vasopressin V2 Receptor (V2R) Antagonist The report ...
January 2022
60 pages
Viral RNA Polymerase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Viral RNA Polymerase Inhibitor The report assesses ...
January 2022
60 pages
Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist The ...
January 2022
60 pages
Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Voltage-Dependent Calcium Channel Blockers The report ...
January 2022
60 pages
Voltage-Dependent T-Type Calcium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Voltage-Dependent T-Type Calcium Channel Blockers The ...
January 2022
60 pages
Voltage-Gated Sodium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Voltage-Gated Sodium Channel Blockers The report ...
January 2022
60 pages
Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Wnt Signaling Pathway Inhibitor The report assesses the active Wnt ...
January 2022
60 pages
Xanthine Oxidase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Xanthine Oxidase Inhibitor The report assesses ...
January 2022
60 pages
Acromegaly and Gigantism Therapeutics - Epidemiology Forecast to 2032
US$ 3,950.00
... 10 Year Forecast 7MM Coverage Total Cases in Acromegaly and Gigantism Therapeutics Key assessments Patient Segmentation in Acromegaly and Gigantism Therapeutics Acromegaly and Gigantism Therapeutics Risk & Burden Factors driving growth in a specific Acromegaly and Gigantism Therapeutics patient population
January 2022
60 pages
Acute Heart failure (AHF) - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Acute Heart failure (AHF) Report Assessment Current Treatment Practices in Acute Heart failure (AHF) Unmet Needs in Acute Heart failure (AHF) Market Attractiveness Market Drivers and Barriers KEY ...
January 2022
200 pages
Acute Heart failure (AHF) - Epidemiology Forecast to 2032
US$ 3,950.00
... respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Acute Heart failure (AHF) Key assessments Patient Segmentation in Acute Heart failure (AHF) Acute Heart failure (AHF) Risk & Burden Factors driving growth in a specific Acute Heart failure (AHF) patient population
January 2022
60 pages
Acute ischemic stroke (AIS) - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Acute ischemic stroke (AIS) Report Assessment Current Treatment Practices in Acute ischemic stroke (AIS) Unmet Needs in Acute ischemic stroke (AIS) Market Attractiveness Market Drivers and Barriers KEY ...
January 2022
200 pages
Acute ischemic stroke (AIS) - Epidemiology Forecast to 2032
US$ 3,950.00
... to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Acute ischemic stroke (AIS) Key assessments Patient Segmentation in Acute ischemic stroke (AIS) Acute ischemic stroke (AIS) Risk & Burden Factors driving growth in a specific Acute ischemic stroke (AIS) patient population
January 2022
60 pages
Acute Lymphoblastic Leukemia Epidemiology Forecast to 2032
US$ 3,950.00
... Key strengths 10 Year Forecast 7MM Coverage Total Cases in Acute Lymphoblastic Leukemia (ALL) Key assessments Patient Segmentation in Acute Lymphoblastic Leukemia (ALL) Acute Lymphoblastic Leukemia (ALL) Risk & Burden Factors driving growth in a specific Acute Lymphoblastic Leukemia (ALL) patient population
January 2022
60 pages
Acute Myeloid Leukemia (AML) - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Acute Myeloid Leukemia (AML) Report Assessment Current Treatment Practices in Acute Myeloid Leukemia (AML) Unmet Needs in Acute Myeloid Leukemia (AML) Market Attractiveness Market Drivers and Barriers KEY ...
January 2022
200 pages
Acute Myeloid Leukemia (AML) - Epidemiology Forecast to 2032
US$ 3,950.00
... the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Acute Myeloid Leukemia (AML) Key assessments Patient Segmentation in Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML) Risk & Burden Factors driving growth in a specific Acute Myeloid Leukemia (AML) patient population
January 2022
60 pages
Age-related Macular Degeneration (AMD) - Epidemiology Forecast to 2032
US$ 3,950.00
... Year Forecast 7MM Coverage Total Cases in Age-related Macular Degeneration (AMD) Key assessments Patient Segmentation in Age-related Macular Degeneration (AMD) Age-related Macular Degeneration (AMD) Risk & Burden Factors driving growth in a specific Age-related Macular Degeneration (AMD) patient population
January 2022
60 pages
AIDS Related Kaposi's Sarcoma - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition AIDS Related Kaposi's Sarcoma Report Assessment Current Treatment Practices in AIDS Related Kaposi's Sarcoma Unmet Needs in AIDS Related Kaposi's Sarcoma Market Attractiveness Market Drivers and Barriers ...
January 2022
200 pages
AIDS Related Kaposi's Sarcoma - Epidemiology Forecast to 2032
US$ 3,950.00
... patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in AIDS Related Kaposi's Sarcoma Key assessments Patient Segmentation in AIDS Related Kaposi's Sarcoma AIDS Related Kaposi's Sarcoma Risk & Burden Factors driving growth in a specific AIDS Related Kaposi's Sarcoma patient population ...
January 2022
60 pages
Allergic Rhinitis - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Allergic Rhinitis Key assessments Patient Segmentation in Allergic Rhinitis Allergic Rhinitis Risk & Burden Factors driving growth in a specific Allergic Rhinitis patient population
January 2022
60 pages
Alzheimer's disease (AD) - Epidemiology Forecast to 2032
US$ 3,950.00
... with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Alzheimer’s disease (AD) Key assessments Patient Segmentation in Alzheimer’s disease (AD) Alzheimer’s disease (AD) Risk & Burden Factors driving growth in a specific Alzheimer’s disease (AD) patient population
January 2022
60 pages
